Detalles de la búsqueda
1.
Navigating the nexus between British Columbia's public consumption and decriminalization policies of illegal drugs.
Health Res Policy Syst
; 22(1): 60, 2024 May 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-38783308
2.
"It's just a perfect storm": Exploring the consequences of the COVID-19 pandemic on overdose risk in British Columbia from the perspectives of people who use substances.
BMC Public Health
; 23(1): 640, 2023 04 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-37013524
3.
"As long as that place stays open, I'll stay alive": Accessing injectable opioid agonist treatment during dual public health crises.
Harm Reduct J
; 20(1): 51, 2023 04 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-37060027
4.
Associations with experience of non-fatal opioid overdose in British Columbia, Canada: a repeated cross sectional survey study.
Harm Reduct J
; 20(1): 178, 2023 Dec 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-38093272
5.
Doing community-based research during dual public health emergencies (COVID and overdose).
Harm Reduct J
; 20(1): 135, 2023 09 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-37715202
6.
Concurrent use of opioids and stimulants and risk of fatal overdose: A cohort study.
BMC Public Health
; 22(1): 2084, 2022 11 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-36380298
7.
Identifying behaviours for survival and wellness among people who use methamphetamine with opioids in British Columbia: a qualitative study.
Harm Reduct J
; 19(1): 46, 2022 05 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-35590375
8.
Smoking identified as preferred mode of opioid safe supply use; investigating correlates of smoking preference through a 2021 cross-sectional study in British Columbia.
Subst Abuse Treat Prev Policy
; 18(1): 27, 2023 05 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-37194018
9.
Awareness, predictors and outcomes of drug alerts among people who access harm reduction services in British Columbia, Canada: findings from a 2021 cross-sectional survey.
BMJ Open
; 13(5): e071379, 2023 05 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37160395
10.
The Impact of Injectable Opioid Agonist Treatment (iOAT) on Involvement in Criminalized Activities: A Secondary Analysis from a Clinical Trial in Vancouver, BC.
Subst Abuse Rehabil
; 14: 147-156, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-38026787
11.
Investigating opioid preference to inform safe supply services: A cross sectional study.
Int J Drug Policy
; 101: 103574, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-35007878
12.
Correlates of concurrent use of stimulants and opioids among people who access harm reduction services in British Columbia, Canada: Findings from the 2019 Harm Reduction Client Survey.
Int J Drug Policy
; 102: 103602, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35124412
13.
Motivations for concurrent use of uppers and downers among people who access harm reduction services in British Columbia, Canada: findings from the 2019 Harm Reduction Client Survey.
BMJ Open
; 12(5): e060447, 2022 05 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-35501101
14.
A multi-methods and longitudinal study of patients' perceptions in injectable opioid agonist treatment: Implications for advancing patient-centered methodologies in substance use research.
J Subst Abuse Treat
; 132: 108512, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34098207
15.
Guideline development in harm reduction: Considerations around the meaningful involvement of people who access services.
Drug Alcohol Depend Rep
; 4: 100086, 2022 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-36846576
16.
Feasibility of Testing Client Preferences for Accessing Injectable Opioid Agonist Treatment (iOAT): A Pilot Study.
Patient Prefer Adherence
; 16: 3405-3413, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36582266
17.
Exploring the effectiveness of dextroamphetamine for the treatment of stimulant use disorder: a qualitative study with patients receiving injectable opioid agonist treatment.
Subst Abuse Treat Prev Policy
; 16(1): 68, 2021 09 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-34530878
18.
Evaluation of risk mitigation measures for people with substance use disorders to address the dual public health crises of COVID-19 and overdose in British Columbia: a mixed-method study protocol.
BMJ Open
; 11(6): e048353, 2021 06 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-34108170
19.
Treatment with injectable hydromorphone: Comparing retention in double blind and open label treatment periods.
J Subst Abuse Treat
; 101: 50-54, 2019 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-31174713
20.
Characteristics and response to treatment among Indigenous people receiving injectable diacetylmorphine or hydromorphone in a randomised controlled trial for the treatment of long-term opioid dependence.
Drug Alcohol Rev
; 37(1): 137-146, 2018 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28593748